Summary
The product Tesamorelin (5mg/vial), with an ironlion-lab manufacturer, underwent independent testing to verify its authenticity and potency. The sample, with an unknown batch number, was submitted by ironlion-lab and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Tesamorelin, with a concentration of 5.46 mg, which is 9.2% above the labeled claim of 5 mg per vial. The product’s purity was determined to be 98.671%.
The testing process began on 27 September 2024, with the sample received on 3 October 2024, and analysis completed on 4 October 2024. While the results confirm high purity, the higher-than-expected concentration raises concerns regarding dosing accuracy. Scrutiny of manufacturer-submitted samples remains essential to ensure reliability. Independent third-party testing remains critical to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: ironlion-lab
- Product Name: Tesamorelin (5mg/vial)
- Active Ingredient: Tesamorelin
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Viral Powder
Sample Acquisition and Testing
- Task Number: #50025
- Testing Ordered: 27 September 2024
- Sample Received: 3 October 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: ironlion-lab (Manufacturer)
- Analysis Paid For By: ironlion-lab (Manufacturer)
Testing Results
- Specification: 5 mg (as stated on the label)
- Measured Concentration: 5.46 mg
- Accuracy: 109.2% (9.2% above the label claim)
- Purity: 98.671%
Verification Details
Verification URL: https://janoshik.com/tests/50025_158DRQK9E8ZC
Evaluation of Manufacturer-Submitted Testing
This analysis highlights that Tesamorelin (5mg/vial) contains Tesamorelin at a high purity level of 98.671%, with a measured amount of 5.46 mg per vial, slightly exceeding the labeled 5 mg specification. While the purity is exceptionally high, the elevated concentration raises concerns about manufacturing consistency and dosing accuracy. Since the test was submitted and funded by ironlion-lab, careful evaluation is necessary to assess product consistency across different batches. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple samples.
Conclusion
The analysis confirms that Tesamorelin (5mg/vial) contains 5.46 mg per vial, which is 9.2% above the labeled claim. The high purity (98.671%) ensures product quality, but the higher-than-expected concentration underscores the importance of further testing to ensure accurate dosing across production batches. This batch exhibits strong quality control, but further independent third-party testing is encouraged to validate consistency across different batches. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding pharmaceutical and peptide products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
